GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report)'s share price passed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $49.32 and traded as low as $49.15. GSK shares last traded at $49.2550, with a volume of 2,949,043 shares trading hands.
Wall Street Analyst Weigh In
Several research firms recently weighed in on GSK. JPMorgan Chase & Co. restated a "sell" rating on shares of GSK in a report on Thursday, October 1st. Jefferies Financial Group cut shares of GSK from a "buy" rating to a "hold" rating and dropped their target price for the stock from $67.40 to $55.90 in a report on Thursday, October 29th. Wolfe Research initiated coverage on shares of GSK in a report on Friday, October 9th. They set an "outperform" rating and a $70.00 target price on the stock. Sanford C. Bernstein reissued a "buy" rating on shares of GSK in a research report on Sunday, August 2nd. Finally, Deutsche Bank restated a "neutral" rating on shares of GSK in a report on Tuesday, September 29th. Three analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat, GSK currently has an average rating of "Hold" and an average target price of $56.30.
Read Our Latest Stock Analysis on GSK
GSK Stock Performance
The company has a debt-to-equity ratio of 1.18, a current ratio of 0.86 and a quick ratio of 0.56. The company has a market cap of $99.63 billion, a PE ratio of 17.11, a price-to-earnings-growth ratio of 2.27 and a beta of 0.29. The business has a fifty day simple moving average of $49.32 and a two-hundred day simple moving average of $52.39.
GSK Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Friday, November 13th will be given a dividend of $0.4518 per share. The ex-dividend date of this dividend is Friday, November 13th. This is an increase from GSK's previous quarterly dividend of $0.4515. This represents a $1.81 dividend on an annualized basis and a yield of 3.7%. GSK's dividend payout ratio is 61.81%.
Hedge Funds Weigh In On GSK
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mondrian Investment Partners LTD grew its position in shares of GSK by 1.1% in the third quarter. Mondrian Investment Partners LTD now owns 4,965,946 shares of the pharmaceutical company's stock valued at $239,210,000 after purchasing an additional 55,116 shares in the last quarter. Equity Investment Corp increased its holdings in shares of GSK by 8.9% in the third quarter. Equity Investment Corp now owns 3,560,824 shares of the pharmaceutical company's stock valued at $171,525,000 after purchasing an additional 291,059 shares during the last quarter. Russell Investments Group Ltd. lifted its position in GSK by 2.1% during the third quarter. Russell Investments Group Ltd. now owns 1,060,376 shares of the pharmaceutical company's stock worth $51,078,000 after buying an additional 22,275 shares in the last quarter. NewEdge Advisors LLC lifted its position in GSK by 842.9% during the second quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company's stock worth $49,986,000 after buying an additional 852,437 shares in the last quarter. Finally, First Trust Advisors LP lifted its position in GSK by 10.5% during the third quarter. First Trust Advisors LP now owns 708,091 shares of the pharmaceutical company's stock worth $34,109,000 after buying an additional 67,456 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.
GSK Company Profile
(
Get Free Report)
GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.